{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hippel+Lindau+Disease&page=2", "query": { "condition": "Hippel Lindau Disease", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hippel+Lindau+Disease&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T10:05:51.250Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01865747", "title": "A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Cabozantinib tablets", "type": "DRUG" }, { "name": "Everolimus (Afinitor) tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 658, "start_date": "2013-06", "completion_date": "2021-01-15", "has_results": true, "last_update_posted_date": "2021-04-27", "last_synced_at": "2026-06-26T10:05:51.250Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01865747" }, { "nct_id": "NCT00075348", "title": "Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Kidney Cancer", "Von Hippel-lindau Syndrome" ], "interventions": [ { "name": "mutation analysis", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2003-12", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-06-26T10:05:51.250Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075348" }, { "nct_id": "NCT01496625", "title": "National Eye Institute Biorepository for Retinal Diseases", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Age-Related Macular Degeneration", "Diabetic Retinopathy", "Von Hippel-Lindau Syndrome", "Retinal Disease", "Retinal Vein Occlusion" ], "interventions": [], "intervention_types": [], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "2 Years to 120 Years" }, "enrollment_count": 650, "start_date": "2012-06-18", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-06-26T10:05:51.250Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01496625" }, { "nct_id": "NCT00001668", "title": "Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Deafness", "Kidney Diseases", "Kidney Neoplasms", "Neoplasms", "Retinal Diseases" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 75, "start_date": "1997-04", "completion_date": "2000-04", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-06-26T10:05:51.250Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001668" }, { "nct_id": "NCT01266070", "title": "TKI 258 in Von Hippel-Lindau Syndrome (VHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Von Hippel-Lindau Syndrome" ], "interventions": [ { "name": "Dovitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2012-11", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-02-13", "last_synced_at": "2026-06-26T10:05:51.250Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01266070" }, { "nct_id": "NCT03001349", "title": "68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Meningioma", "Metastatic Well Differentiated Neuroendocrine Neoplasm", "Multiple Endocrine Neoplasia Type 1", "Neuroendocrine Neoplasm", "Somatostatin Positive Neoplastic Cells Present", "Von Hippel-Lindau Syndrome" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68-Edotreotide", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 4, "start_date": "2017-05-16", "completion_date": "2021-02-05", "has_results": false, "last_update_posted_date": "2021-02-15", "last_synced_at": "2026-06-26T10:05:51.250Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03001349" }, { "nct_id": "NCT04895748", "title": "DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "DFF332", "type": "DRUG" }, { "name": "RAD001", "type": "DRUG" }, { "name": "PDR001", "type": "DRUG" }, { "name": "NIR178", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 40, "start_date": "2021-11-30", "completion_date": "2026-02-13", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-06-26T10:05:51.250Z", "location_count": 5, "location_summary": "Duarte, California • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895748" }, { "nct_id": "NCT03050268", "title": "Familial Investigations of Childhood Cancer Predisposition", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Leukemia", "Adenomatous Polyposis", "Adrenocortical Carcinoma", "AML", "BAP1 Tumor Predisposition Syndrome", "Carney Complex", "Choroid Plexus Carcinoma", "Constitutional Mismatch Repair Deficiency Syndrome", "Diamond-Blackfan Anemia", "DICER1 Syndrome", "Dyskeratosis Congenita", "Emberger Syndrome", "Familial Acute Myeloid Leukemia", "Familial Adenomatous Polyposis", "Fanconi Anemia", "Familial Cancer", "Familial Wilms Tumor", "Familial Neuroblastoma", "GIST", "Hereditary Breast and Ovarian Cancer", "Hereditary Paraganglioma-Pheochromocytoma Syndrome", "Hodgkin Lymphoma", "Juvenile Polyposis", "Li-Fraumeni Syndrome", "Lynch Syndrome", "MDS", "Melanoma Syndrome", "Multiple Endocrine Neoplasia Type 1", "Multiple Endocrine Neoplasia Type 2", "Neuroblastoma", "Neurofibromatosis Type 1", "Neurofibromatosis Type II", "Nevoid Basal Cell Carcinoma Syndrome", "Non Hodgkin Lymphoma", "Noonan Syndrome and Other Rasopathy", "Overgrowth Syndromes", "Pancreatic Cancer", "Peutz-Jeghers Syndrome", "Pheochromocytoma/Paraganglioma", "PTEN Hamartoma Tumor Syndrome", "Retinoblastoma", "Rhabdoid Tumor Predisposition Syndrome", "Rhabdomyosarcoma", "Rothmund-Thomson Syndrome", "Tuberous Sclerosis", "Von Hippel-Lindau Disease" ], "interventions": [], "intervention_types": [], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1500, "start_date": "2017-04-06", "completion_date": "2037-03-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-26T10:05:51.250Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03050268" }, { "nct_id": "NCT00056199", "title": "EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hippel-Lindau Disease" ], "interventions": [ { "name": "EYE001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5, "start_date": "2003-03", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-06-26T10:05:51.250Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00056199" }, { "nct_id": "NCT00566995", "title": "Phase II Study of Vandetanib in Individuals With Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cancer", "Von Hippel Lindau" ], "interventions": [ { "name": "ZACTIMA (Vandetanib) (ZD6474)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 37, "start_date": "2008-02-07", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2018-10-30", "last_synced_at": "2026-06-26T10:05:51.250Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00566995" } ] }